October 10, 2024 - Rutgers Cancer Institute and Worldwide Innovative Network (WIN) in personalized cancer medicine consortium have joined forces to advance innovative cancer research.
“We are very proud to welcome Rutgers Cancer Institute to WIN,” said Dr. Wafik S. El-Deiry, Chair of WIN Consortium, and Director, Legorreta Cancer Center, Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University, “Rutgers Cancer Institute together with RWJBarnabas Health is one of an elite group of National Cancer Institute (NCI)-Designated Comprehensive Cancer Centers and the only one in the state of New Jersey. This coveted designation gives Rutgers Cancer Institute the distinction of being among the best cancer research institutions in the U.S. Rutgers Cancer Institute has amazing colleagues who we are excited to collaborate with through innovative next-generation precision oncology trials.”
WIN was the first consortium that assembled all stakeholders of cancer care, from academia, industry, and patient advocates to work together across the globe. It was also the first organization to launch a N-of-One study using transcriptomics in addition to genomics to inform therapeutic choice in the WINTHER study. “It is with great excitement that we at WIN welcome Rutgers Cancer Institute, which is a leading cancer institution, and its talented faculty,” said Dr Razelle Kurzrock, Chief Medical OQicer of WIN, Professor of Medicine, Associate Director Clinical Research, MCW Cancer Center and Linda T. & John A. Mellowes of Precision Oncology.
“Joining the global WIN Consortium strengthens our mission to improve cancer outcomes worldwide,” said Dr. Steven K. Libutti, Director, Rutgers Cancer Institute and Senior Vice President, Oncology Services, RWJBarnabas Health. “This partnership allows us to collaborate on cutting-edge research and leverage the expertise of leaders in the field, all aimed at delivering more personalized and eMective cancer care. With the Jack and Sheryl Morris Cancer Center opening in 2025, we are even better positioned to innovate and enhance treatment for our patients.”
About WIN Consortium
WIN Consortium is a non-profit association headquartered in France. The WIN network assembles 37 worldclass academic medical centers, industries, research organizations and patient advocates spanning 20 countries and 4 continents, aligned to launch trials to bolster Precision Oncology across the world. WIN is the organizer of the WIN symposia in Precision Oncology.
MEDIA CONTACTS:
www.winconsortium.org
Catherine Bresson, Director Operational Team
catherine.bresson@winconsortium.org